GLP-1 receptor agonists for obesity: eligibility across 99 countries

  • Sang Gune K. Yoo*
  • , Felix Teufel
  • , Michaela Theilmann
  • , Yajuan Si
  • , Elhadji A Toure
  • , Krishna K Aryal
  • , Till W Bärnighausen
  • , Abdul Bait
  • , Marta Barreto
  • , Pascal Bovet
  • , Luisa CC Brant
  • , Sarah Cuschieri
  • , Albertino Damasceno
  • , Farshad Farzadfar
  • , Asher Fawwad
  • , Pascal Geldsetzer
  • , Ian Hambleton
  • , Corine Houehanou
  • , Christina Howitt
  • , Jutta M A Jorgensen
  • Juan P González-Rivas, Demetre Labadarios, Maja Marcus, Joao Martins, Omar Mwalim, Ramfis NietoMartínez, Augustine N Odili, Binur Orazumbekova, Gastón Perman, Sarah Quesnel-Crooks, Sahar Saeedi Moghaddam, Ronel Sewpal, Mafalda Sousa-Uva, Mubarak Ayodeji Sulola, Kavita Venkataraman, Sebastian Vollmer, Xueling Sim, Rifat Atun, José R Banegas, Juan VA Franco, Clare Arnott, Nomathemba Chandiwana, Mark D. Huffman, Justine Davies, Mohammed K. Ali, David Flood, Jennifer Manne-Goehler
*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)105-108
Number of pages4
JournalThe Lancet Diabetes and Endocrinology
Volume14
Issue number2
Early online date8 Jan 2026
DOIs
Publication statusPublished - Feb 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Obesity
  • Non-communicable disease
  • Pharmacoepidemiology
  • Global Health

Cite this